Chris Sampson
Publications and Insights
- Bulletin: The disputed calculus of life
- Publication: The impact of inflation on incremental costs in HTA
- Insight: NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
- Publication: The value of cell and gene therapies to the UK economy
- Insight: Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
- Bulletin: 2025: all change, please
- Insight: Infectious disease: another reason to try Veganuary for the NHS
- Publication: A Framework for Value-aligned Pricing of Combination Therapies
- Insight: Around the World in HTAs: United States – Making HTA Great Again
- Insight: Could Plant-based Diets Transform Health Care Spending?
- Publication: The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
- Insight: Sleepio: Lessons from the Frontier of Digital Therapeutics
- Insight: To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
- Publication: How is Quality of Life Measured for Health Technology Assessments?
- Publication: Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?
- Publication: How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
- Publication: The Impact of New Medicines in the NHS: 70 Years of Innovation
- Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
- Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom